Table 3 Antibiotic-resistance profile of MDR strains and AgNPs susceptibility test
Bacteria | Tested antibiotics | Disk content (µg) | ZOI (mm) | Antibiotics susceptibility interpretationa |
|---|---|---|---|---|
ESBL+ve E. coli | Nalidixic acid | 30 | 6.0 ± 0.50 | R |
Doxycycline | 30 | 16.16 ± 0.28 | S | |
Norfloxacin | 10 | 8.0 ± 0.50 | R | |
Nitrofurantoin | 30 | 15.0 ± 0.50 | I | |
Cefixime | 30 | 6.0 ± 0.50 | R | |
Cefixime/clavulanate | 5/10 | 8.0 ± 0.50 | R | |
Cefoperazone | 75 | 6.0 ± 0.0 | R | |
Cefoperazone/tazobactam | 75/10 | 19.5 ± 1.0 | S | |
Ceftazidime | 30 | 7.0 ± 1.0 | R | |
Cetazidime/clavulanate | 30/10 | 14.0 ± 0.0 | I | |
Chloramphenicol | 30 | 15.16 ± 0.28 | I | |
Cefprozil | 30 | 6.5 ± 0.50 | R | |
Cefepime | 30 | 10.5 ± 0.50 | R | |
AgNPs | 2.16b | 10.5 ± 0.50 | – | |
AgNO3 | 3.4 | 9.16 ± 0.28 | – | |
Sterile H2O | 20 µl | 0 ± 0 | – | |
S. aureus (MRSA) | Oxacillin | 1 | 6.66 ± 0.28 | R |
Cefoxitin | 30 | 19.33 ± 0.57 | R | |
AgNPs | 2.16b | 13.5 ± 0.5 | – | |
AgNO3 | 3.4 | 11.0 ± 0.0 | – | |
Sterile H2O | 20 µl | 0 ± 0 | – | |
S. pneumoniae MDR | Teicoplanin | 30 | 10.0 ± 0.0 | R |
AgNPs | 2.16b | 13.16 ± 0.28 | – | |
AgNO3 | 3.4 | 11.0 ± 0.0 | – | |
Sterile H2O | 20 µl | 0 ± 0 | – |